← FDA DRUG APPROVALS

FDA ANDA · ANDA090722

LEVOFLOXACIN

Sponsor: TORRENT PHARMS

APPLICATION
ANDA090722
TYPE
ANDA
ORIGINAL APPROVAL
2011-06-20
LATEST ACTION
2024-09-20
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

LEVOFLOXACINDiscontinued
LEVOFLOXACIN 750MG · TABLET · ORAL
LEVOFLOXACINDiscontinued
LEVOFLOXACIN 250MG · TABLET · ORAL
LEVOFLOXACINDiscontinued
LEVOFLOXACIN 500MG · TABLET · ORAL

Approval history

2024-09-20Labeling · Supplement 16 · standardAP
2023-06-21Labeling · Supplement 15 · standardAP
2019-05-03Labeling · Supplement 14 · standardAP
2019-04-17Labeling · Supplement 12 · standardAP
2019-04-17Labeling · Supplement 10 · standardAP
2019-04-17Labeling · Supplement 13 · standardAP
2019-04-17Labeling · Supplement 11 · standardAP
2014-11-08Labeling · Supplement 8 · standardAP
2014-11-08Labeling · Supplement 7 · standardAP
2012-07-25Labeling · Supplement 4 · standardAP
2012-01-23Labeling · Supplement 2AP
2011-11-02Labeling · Supplement 1AP
2011-06-20OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →